















# Averting Stock Outs with QuanTB: Implementation Experience and Lessons Learned from the SIAPS Program

Aubrey Clark
Sameh Saleeb
Management Sciences for Health/SIAPS Program

Chinwe Owunna

November 16, 2016

GHSCS - Dar Es Salaam, Tanzania





# **Outline**

TB supply chain challenges and SIAPS response

Activities, results and lessons learned

Conclusion





# **Challenges in TB Supply Chain Management**

- Rapid changes in TB program Programmatic
   Management of Drug Resistant TB program expansion
  - Late initiation of procurements, delayed deliveries
  - Deficiencies in MIS system poor data quality
  - Over estimation/ ambitious scale up targets
  - Weak HR capacity and ineffective tools for quantification of drug resistant TB medicines —




- Overstocks, expiries and wastage of expensive medicines
- Widespread stock-outs of medicines



# **SIAPS** Response

- Development of QuanTB tool free downloadable desktop application to improve procurement processes, ordering and supply planning for TB treatment.
- Provide technical assistance to select countries to establish an early warning system (EWS) to prevent stock-outs and minimize wastage of TB medicines.







# **Our Approach**



Technical assistance through country resident or regional advisors



Stakeholder coordination and collaboration




Capacity and skills building





# **Target Countries**

Region	Target Countries
Africa	Tanzania Uganda Kenya Zambia Zimbabwe Ethiopia South Sudan Nigeria DRC Mozambique
Asia	Bangladesh Philippines Burma Uzbekistan Tajikistan







# **Technical Support Activities (1/2)**

# Rapid PSM system assessment

 Participated in GDF and TB program review missions to assess and recommend PSM areas targeted for improvement

# Forecasting and Supply Planning

- Established/strengthened quantification TWG
- Organized quantification training meetings involving NTPs and in-country stakeholders
- Provided TA in annual/multi-year TB medicines forecasting and semi-annual reviews

Implementation of EWS to prevent TB medicines stock outs and minimize wastage

- Supported NTPs and TWG to ensure regular monitoring of stock status
- Supported quantification TWG to interpret EWS results and recommend immediate actions to avoid stock-outs and wastages





# **Technical Support Activities (2/2)**

Strengthening MIS and improving data quality

- Supported development/revision MIS tools
- Collaborated with local partners to improve MIS

Development of MOHs strategic documents and resource mobilization

- Participated in NSP development focusing on PSM
- Contributed to TGF concept note writing
- Supported development of supply chain guidelines and job aids

Improving coordination between MOHs agencies, donors and IPs

- Supported stakeholder coordination meetings
- Collaborated with in-country partners to address
   TB supply chain challenges
- Liaise with GDF/GF on behalf of NTP to facilitate EWS action requests





# **Summary Table**

Parameters Summar	y Medicines i	Report   Case	s Report   Med	dicines Detailed F	Report   Order	and Schedule	Graphs						
Cepina Exercise 4 Chin													
Medicine	On the inventory date Mar 31, 2016		Accelerated order period Apr 01, 2016Aug 31, 2016 (153 days)			Regular order period Sep 01, 2016Sep 30, 2017 (395 days)					Estimated missed quantity Apr 01, 2016Sep 30, 2017 (548 days)		
	Stock on hand	Estim. months of stock (incl. buffer, excl. on order)	Stock on order	Quantity dispensed	Quantity likely to expire	Stock on hand after accelerated order period	Stock on order	Quantity likely to expire	Estimated consumption (enrolled cases)	Estimated consumption (expected cases)	Regular order period	Accelerated order period	Total
Capreomycin 1000mg Powder for injection	81,000	9	0	20,321	-	60,679	-	22,053	806	146,380	108,560	-	108,560
Kanamycin 1000mg Powder for injection	40,400	8	20000	15,156	-	45,244	-	-	806	98,540	54,102	-	54,102
Cycloserine 250mg Capsule(s)	335,000	9	0	71,898	-	263,102	-	128,462	69,999	628,680	564,039	-	564,039
Ethionamide 250mg Film coated tablet(s)	140,000	8	0	63,837	-	76,163	-	-	64,986	425,880	414,703	-	414,703





# **Dashboard**


## Inventory date: Mar 31, 2016 Total enrolled cases: 165 Total expected cases: 1,640







# **Individual Medicine Graph**



# **Order Scheduling Table**

Schedule of orders: Annually											
Accelerated order # 1 Order date: As soon as possible Delivery date: As soon as possible	ble (should have bee ble (should have bee			Regular order # 1 Order date: Apr 1, 2016 Delivery date: Sep 1, 2016							
Medicines	Adjusted quantity to order (in units)  Adjusted quantity to order rounded up to pack size		Cost	Medicines	Adjusted quantity to order (in units)	Adjusted quantity to order rounded up to pack size	Cost				
Eto(250) Ethionamide 250mg Film coated tablet(s)	89,452	895	7,151.05	Cm(1000) Capreomycin 1000mg Powder for injection	49,067	49,067	230,614.90	^			
Lfx(250) Levofloxacin 250mg Film coated tablet(s)	135,120	1,352	7,436.00	Km(1000) Kanamycin 1000mg Powder for injection	29,142	2,915	74,624.00				
PAS(Na) P-aminosalicylate sodium salt 4000mg Po	2,968	119	4,075.75	Cs(250) Cycloserine 250mg Capsule(s)	251,028	2,511	54,162.27				
Pto(250) Protionamide 250mg Film coated tablet(s)	7,258	73	1,295.75	Eto(250) Ethionamide 250mg Film coated tablet(s)	170,517	1,706	13,630.94				
Z(500) Pyrazinamide 500mg Film uncoated tablet(s)	332,280	495	10,395.00	Lfx(250) Levofloxacin 250mg Film coated tablet(s)	191,823	1,919	10,554.50				
				PAS(Na) P-aminosalicylate sodium salt 4000mg Po	113,678	4,548	155,769.00				
				Pto(250) Protionamide 250mg Film coated tablet(s)	246,876	2,469	43,824.75	V			
Cost of medicines:			30,353.55	Cost of medicines:			600,589	.36			
Additional cost:			0.00	Additional cost:			0.	0.00			
Cost of order:			30,353.55	Cost of order:			600,589	.36			
Regular order # 2 Order date: Aug 1, 2016 Delivery date: Jan 1, 2017											
Medicines	order (in linits)	Adjusted quantity to order rounded up to pack size	Cost								





# Results (1)

- Improved decision making based on evidence to avert stock-outs and reduce wastage
  - Emergency orders
  - Expedite deliveries
  - Postpone/cancel orders
  - Redistribution of stock
- Provided evidence for fund request justification and advocacy for more funds for procurement
- Improved coordination between in country stakeholders





# Results (2)

- Helped identify other challenges example
  - Non adherence to treatment guidelines
  - Data quality issues
  - Weakness in inventory management (FEFO)
- Minimized wastage
  - Early detection of potential expiries
  - Savings of over 10 million USD (2014 -2016) as a result of order cancelation, postponement and cross boarder transfers



# Results (3)









# **Limitations**

- Unfulfilled procurement commitments
- Prolonged procurement lead times
- Lack of rapid response mechanism in case of overstocks or potential expiries
- Huge variation between forecasts and actual consumption, leading to overstocks
- Staff turnover or transfers
- Delayed approvals and fund disbursement



# **Lesson Learned**

- A national quantification mechanism responsible for regular stock status monitoring is essential.
- EWS alert actions when not executed in a timely manner can still result in supply chain risks.
- Countries need to provide evidence to donors to justify why realistic targets based on historical data and not ambitious targets should be used for procurement.
- Weak and delayed data reports for quantification contributes to inaccurate results and risks to the system.
- Government fund commitments for procurement are not always accessed on time.





## **Conclusion**

- Implementation of an early warning system and use of targeted technical assistance to build capacity at country level is an effective approach to ensure continuous access to medicines.
- Early warning system alerts if not acted on can still lead to supply chain risks.
- Financial, skilled, dedicated human resources and a functional SC system is essential for success.
- For sustainability, countries should institutionalize
   EWS process and take full ownership



# Download: <a href="http://siapsprogram.org/quantb/">http://siapsprogram.org/quantb/</a>





# Version 4 now available on SIAPS website for download





# For your information

Will be available on leadernet.org in December 2016











www.shutterstock.com · 231282988



